March Altus Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

March Altus Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$201K	Buy	+500	New	+$201K	1.26%	11
2016 Q2	–	Sell	-2,291	Closed	-$826K	–	9
2016 Q1	$826K	Sell	2,291 -625	-21%	-$258K	8.55%	6
2015 Q4	$1.58M	Buy	2,916 +1,160	+66%	+$628K	14.56%	3
2015 Q3	$817K	Sell	1,756 -538	-23%	-$289K	4.81%	8
2015 Q2	$1.17M	Sell	2,294 -98	-4%	-$47.8K	6.8%	5
2015 Q1	$1.08M	Sell	2,392 -27,228	-92%	-$11.5M	6.79%	6
2014 Q4	$12.2M	Buy	+29,620	New	+$11.6M	5.55%	7

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

March Altus Capital Management's REGN Position: Q3 2016 in Review

March Altus Capital Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2016: 500 shares worth $201K. The stake represents 1.26% of the portfolio and ranks #11 among its holdings. This is a return to the name: March Altus Capital Management previously reported a position in REGN as recently as Q1 2016.

March Altus Capital Management first reported a position in REGN in Q4 2014 and has held it in 7 quarters since. The position peaked at $12.2M in Q4 2014. 554 funds tracked by Wall St. Rank hold REGN as of Q3 2016.

March Altus Capital Management held 500 shares of Regeneron Pharmaceuticals worth $201K as of Q3 2016.
Regeneron Pharmaceuticals was a new March Altus Capital Management position in Q3 2016.
Regeneron Pharmaceuticals made up 1.26% of March Altus Capital Management's portfolio in Q3 2016, its #11 holding.
March Altus Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 7 quarters since.
March Altus Capital Management's Regeneron Pharmaceuticals position peaked at $12.2M in Q4 2014.
554 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2016.

Based on March Altus Capital Management's 13F filing for Q3 2016, filed 7 Nov 2016.